AbbVie's Fourth Humira Patent Settlement Allows Sandoz Biosimilar US Entry Eight Months After Amgen

Sandoz joins list of companies that opt to settle rather than challenge AbbVie's hefty patent portfolio; staggered launches offer model for future deals.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.

Sandoz Inc. is the fourth company to opt to settle with AbbVie Inc. rather than battle over its vast Humira (adalimumab) patent portfolio.

Under the terms of the agreement, announced Oct. 11, Sandoz will be able to launch its proposed biosimilar Hyrimoz in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics